<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273479</url>
  </required_header>
  <id_info>
    <org_study_id>9.127</org_study_id>
    <nct_id>NCT02273479</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of Asasantin Extended Release (RAD-SP) Capsules in Japanese Healthy Male Volunteers</brief_title>
  <official_title>Pharmacokinetics and Safety of Asasantin Extended Release (RAD-SP) 200/25 mg Capsules b.i.d. in Randomised, Double-blind, Placebo-controlled Study in Japanese Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate pharmacokinetics, pharmacodynamics and safety of RAD-SP capsule in
      multiple administration to healthy adult male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1999</start_date>
  <primary_completion_date type="Actual">September 1999</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma drug concentration-time curve at steady state (AUCss)</measure>
    <time_frame>up to 144 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum drug plasma concentration at steady state (Cmax,ss)</measure>
    <time_frame>up to 144 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss/AUCss</measure>
    <time_frame>up to 144 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum drug plasma concentration at steady state (Cmin,ss)</measure>
    <time_frame>up to 144 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (tmax)</measure>
    <time_frame>up to 144 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>up to 144 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>up to 144 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent peak trough fluctuation (%PTF)</measure>
    <time_frame>up to 144 hours after first drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet adenosine uptake inhibition rate (AUI)</measure>
    <time_frame>up to 74 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malondialdehyde (MDA) production inhibition rate</measure>
    <time_frame>up to 74 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboxane B2 (TXB2) production inhibition rate</measure>
    <time_frame>up to 74 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal changes in laboratory parameters</measure>
    <time_frame>up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal changes in vital signs</measure>
    <time_frame>up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal changes in electrocardiogram findings</measure>
    <time_frame>up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Asasantin®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asasantin®</intervention_name>
    <description>Asasantin® extended release (RAD-SP)</description>
    <arm_group_label>Asasantin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers judged by the investigator as appropriate subjects on the
             basis of screening test results

          -  Age range: ≥ 20 years and ≤ 35 years

          -  Body weight between 50 and 80 kg

          -  Obesity is within ± 20% of the standard body weight

          -  Ability to provide written informed consent to participate in the study

        Exclusion Criteria:

          -  History of drug allergy

          -  History of bronchial asthma

          -  History of drug abuse and alcohol abuse

          -  History of hemorrhagic tendency or hemorrhagic disease

          -  Volunteers who have experiences in playing sports such as boxing which may damage the
             brain

          -  Accidents associated with brain concussion and contusion (traffic accident, etc.)

          -  Administration of other study drug within 4 months before start of administration of
             this study drug

          -  Collection of whole blood (≥ 400 ml) within 3 months before study drug administration

          -  Collection of component blood (≥ 400 ml) within 1 months before study drug
             administration

          -  Intake of some drug or other within 10 days before the study drug administration

          -  Excessive physical activities within the last 5 days prior to study drug
             administration

          -  Intake of alcohol within 3 days before study drug administration

          -  Volunteers judged by the investigator to be inappropriate as the subjects of study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>October 23, 2014</last_update_submitted>
  <last_update_submitted_qc>October 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin, Dipyridamole Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

